Site
Search results
U.S. FDA Approves IMBRUVICA® (ibrutinib) as First and Only Approved Treatment for Adult Patients with Chronic Graft-Versus-Host-Disease (cGVHD) After Failure of One or More Lines of Systemic Therapy
Aug 02, 2017 United States The approval provides an important new treatment option for adults living with debilitating and potentially life-threatening condition This is the first indication for IMBRUVICA outside of oncology and its sixth U.S. indication ...